Crinetics Pharmaceuticals, Inc.
CRNX
Rang in aandelen
#2240
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Aandeelprijs
$84.95
Laatst gesynchroniseerd: 2026-09-01
Marktkapitalisatie
$9.00B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
98.25%
Land
US
Handel Crinetics Pharmaceuticals, Inc. (CRNX)
Categorie
Healthcare
P/B-ratio voor Crinetics Pharmaceuticals, Inc. (CRNX)
P/B-ratio op October 2026 TTM: 7.52
Volgens de meest recente financiële rapporten en aandelenkoers van Crinetics Pharmaceuticals, Inc. is de huidige P/B-ratio (TTM) 7.52. Eind 2023 had het bedrijf een P/B-ratio van 3.83.
P/B-ratiohistoriek voor Crinetics Pharmaceuticals, Inc. van 2016 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 7.52 | 141.13% |
| 2024 | 3.12 | -18.65% |
| 2023 | 3.83 | 27.45% |
| 2022 | 3.01 | -8.58% |
| 2021 | 3.29 | 29.34% |
| 2020 | 2.54 | -139.33% |
| 2019 | -6.47 | -22.97% |
| 2018 | -8.39 | -62.93% |
| 2017 | -22.64 | -58.70% |
| 2016 | -54.83 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| 6.251 | -16.91% |
US
|
|
| 13.2547 | 76.18% |
US
|
|
| 4.208 | -44.07% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -17.82% |
NL
|
